Table 1.
Baseline characteristics at the time of diagnosis
| Variable | Total | ESKD | Non-ESKD | p-value |
|---|---|---|---|---|
| No. of patients | 92 | 45 | 47 | |
| Age (yr) | 61.0 ± 15.3 | 63.4 ± 15.4 | 57.1 ± 15.6 | 0.055 |
| Male sex | 46 (50.0) | 24 (53.3) | 22 (46.8) | 0.532 |
| Comorbid disease | ||||
| Diabetes | 11 (12.0) | 6 (13.3) | 5 (10.6) | 0.690 |
| Hypertension | 31 (33.7) | 21 (46.7) | 10 (21.3) | 0.010 |
| Follow-up after diagnosis (day) | 475.0 (87.0–1,268.0) | 357.0 (68.0–1,344.0) | 677.0 (320.0–1,175.0) | 0.152 |
| Laboratory data | ||||
| eGFR (mL/min/1.73 m2) | 13.2 (8.1–25.5) | 8.6 (7.0–13.2) | 24.0 (12.9–40.2) | <0.001 |
| Spot urine protein-to-creatinine ratio (g/g) | 2.2 (1.5–3.9) | 2.1 (1.5–4.1) | 2.3 (1.5–3.8) | 0.645 |
| Immunologya | 0.267 | |||
| MPO-ANCA | 86 (93.5) | 41 (91.1) | 45 (95.7) | |
| PR3-ANCA | 7 (7.6) | 5 (11.1) | 2 (4.3) | |
| Histopathologic findings | ||||
| Total glomeruli number | 16.0 (12.0–23.0) | 16.0 (12.0–24.0) | 16.0 (12.0–22.0) | 0.427 |
| Normal glomeruli (%) | 20.4 (8.3–39.1) | 9.1 (0.0–18.6) | 33.3 (20.8–50.0) | <0.001 |
| Crescentic glomeruli (%) | 54.2 (30.8–70.4) | 58.3 (32.4–76.1) | 50.0 (30.0–69.2) | 0.124 |
| Globally sclerotic glomeruli (%) | 14.8 (0.0–30.2) | 23.3 (6.3–38.8) | 8.3 (0.0–23.1) | 0.004 |
| IF/TA, >25% | 42 (45.7) | 29 (64.4) | 13 (27.7) | <0.001 |
| Histopathologic classification | 0.003 | |||
| Focal | 18 (19.6) | 3 (6.7) | 15 (31.9) | |
| Crescentic | 30 (32.6) | 14 (22.2) | 16 (34.0) | |
| Mixed | 32 (34.8) | 18 (40.0) | 14 (29.8) | |
| Sclerotic | 12 (13.0) | 10 (22.2) | 2 (4.3) | |
| ANCA kidney risk scoreb | 5.0 (2.0–11.0) | 9.0 (6.0–11.0) | 2.0 (0–5.0) | <0.001 |
| Clinicopathologic classification | <0.001 | |||
| Low | 21 (22.8) | 2 (4.4) | 19 (40.4) | |
| Medium | 39 (42.4) | 15 (33.3) | 24 (51.1) | |
| High | 32 (34.8) | 28 (62.2) | 4 (8.5) |
Data are expressed as number only, mean ± standard deviation, median (interquartile range), or number (%).
ANCA, anti-neutrophil cytoplasmic antibody; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; IF/TA, interstitial fibrosis/tubular atrophy; MPO, myeloperoxidase; PR3, proteinase 3.
a
One patient (1 of 92, 1.1%) had positivity for both MPO- and PR3-ANCA.
b
Sum score of the clinicopathologic parameters (percentage of normal glomeruli, degree of IF/TA, and eGFR at the time of diagnosis).